• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4610651)   Today's Articles (135)   Subscriber (49380)
For: Tanimoto K, Muranski P, Miner S, Fujiwara H, Kajigaya S, Keyvanfar K, Hensel N, Barrett AJ, Melenhorst JJ. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells. Cytotherapy 2013;16:135-46. [PMID: 24176543 DOI: 10.1016/j.jcyt.2013.08.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2013] [Revised: 08/13/2013] [Accepted: 08/21/2013] [Indexed: 02/06/2023]
Number Cited by Other Article(s)
1
Talebi M, Nozad Charoudeh H, Movassaghpour Akbari AA, Baradaran B, Kazemi T. Effect of Cellular-Based Artificial Antigen Presenting Cells Expressing ICOSL, in T-cell Subtypes Differentiation and Activation. Adv Pharm Bull 2021;11:537-542. [PMID: 34513629 PMCID: PMC8421621 DOI: 10.34172/apb.2021.062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 06/16/2020] [Accepted: 08/05/2020] [Indexed: 12/17/2022]  Open
2
Toward precision manufacturing of immunogene T-cell therapies. Cytotherapy 2018;20:623-638. [DOI: 10.1016/j.jcyt.2017.12.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 12/14/2017] [Accepted: 12/14/2017] [Indexed: 12/27/2022]
3
Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Cytotherapy 2016;18:570-80. [DOI: 10.1016/j.jcyt.2016.01.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 12/01/2015] [Accepted: 01/05/2016] [Indexed: 11/23/2022]
4
Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther 2015;22:67-71. [DOI: 10.1038/cgt.2014.71] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 11/05/2014] [Indexed: 01/13/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA